| |  Online-Ressource |
|---|
| Verfasst von: | Schmoch, Thomas [VerfasserIn]  |
|---|
| | Heininger, Alexandra [VerfasserIn] |
|---|
| | Richter, Daniel [VerfasserIn] |
|---|
| | Brenner, Thorsten [VerfasserIn] |
|---|
| | Weigand, Markus A. [VerfasserIn] |
|---|
| Titel: | Differentiated treatment of multi-resistant Gram-negative pathogens in intensive care units |
|---|
| Verf.angabe: | T. Schmoch, A. Heininger, D. Richter, T. Brenner, M.A. Weigand |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | September 2021 |
|---|
| Umfang: | 12 S. |
|---|
| Fussnoten: | Gesehen am 03.11.2021 |
|---|
| Titel Quelle: | Enthalten in: Anästhesiologie & Intensivmedizin |
|---|
| Ort Quelle: | Ebelsbach : Aktiv Dr. und Verl., 1978 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 62(2021) vom: Sept., Seite 398-409 |
|---|
| ISSN Quelle: | 1439-0256 |
|---|
| Abstract: | Multi-resistant Gram-negative pathogens will pose an enormous challenge to medicine in the coming years. Therefore, the World Health Organization emphasises that there is a great need for the development of new antimicrobial drugs. At the same time, intensivists must be prepared to treat complex infections with multi-resistant pathogens more often. As a consequence, a sound knowledge of the resistance mechanisms and the available antimicrobial drugs is essential. In this context, new beta-lactam antibiotics (and combinations), such as ceftolozane / tazobactam or ceftazidime / avibactam, but also the combinations of / with meropenem / vaborbactam, aztreonam / avibactam or imipenem / cilastatin / relebactam, should be mentioned. Their availability is to be welcomed, especially with regard to their reduced toxicity in comparison to colistin-based therapies. Moreover, this review comments on cefiderocol, a new drug which could revolutionise the treatment of multi-resistant Gram-negative germs. This review article intends to give the reader an overview of the resistance mechanisms prevalent in Germany and the respective appropriate treatment options. |
|---|
| DOI: | doi:10.19224/ai2021.398 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.19224/ai2021.398 |
|---|
| | Volltext: https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=DynamicDOIArticle&SrcApp=WOS&KeyAID=10.19224% ... |
|---|
| | DOI: https://doi.org/10.19224/ai2021.398 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | ger eng |
|---|
| Sach-SW: | aerosolized colistin |
|---|
| | beta-lactamase inhibitor |
|---|
| | Cefiderocol |
|---|
| | Ceftazidime / Avibactam |
|---|
| | ceftazidime-avibactam |
|---|
| | Ceftolozane / Tazobactam |
|---|
| | double-blind |
|---|
| | in-vitro activity |
|---|
| | klebsiella-pneumoniae |
|---|
| | meropenem |
|---|
| | Multi-resistant Gram-negative |
|---|
| | nosocomial pneumonia |
|---|
| | piperacillin-tazobactam |
|---|
| | pseudomonas-aeruginosa |
|---|
| | Sepsis |
|---|
| K10plus-PPN: | 1776027310 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Differentiated treatment of multi-resistant Gram-negative pathogens in intensive care units / Schmoch, Thomas [VerfasserIn]; September 2021 (Online-Ressource)
